GovWire

A review of the evidence of use and harms of novel benzodiazepines.

Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).

Three new members of the Advisory Council for the Misuse of Drugs (ACMD) have been announced today.

ACMD public request for written evidence on cognition enhancers (also known as ‘nootropics’ or ‘study drugs’).

Forms for members of the public to provide written evidence on young people’s drug use and naloxone provision.

A letter from the Minister of State for Fire and Policing to the ACMD, in response to the recommendation to Schedule Epidyolex.

This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government.

Letter from ACMD to ministers, providing advice on the administration rights of morphine by injection for therapeutic radiographer independent prescribers.

Letter from the ACMD Barriers to Research working group to collect written evidence from researchers about barriers to legitimate research with controlled drugs.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Secretary advising on COVID-19 emergency measures to enable the supply of controlled drugs.

A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.

Forms for members of the public to provide written evidence on young people’s drug use and naloxone provision.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Secretary in response to the 6 January letter on GHB and GBL.

Letter from the ACMD Barriers to Research working group to collect written evidence from researchers about barriers to legitimate research with controlled drugs.

Letter from the ACMD Barriers to Research working group to collect written evidence from researchers about barriers to legitimate research with controlled drugs.

Register your interest in attending or providing evidence to the ACMD.

Letter to the Home Office regarding the appropriate Schedule for the cannabis-based product for medicinal use, Epidyolex, under the Misuse of Drugs Regulations 2001.

This report advises government on the number and nature of known fentanyl analogues, risk factors, pharmacology, toxic effects and misuse and associated harms.

A framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use (CBPMs).

A framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use (CBPMs).

Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs, outlining our self-commissioned workstreams planned for 2020.

Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs, outlining our self-commissioned workstreams planned for 2020.

Report to the Minister for Crime Prevention, which recommends a revised generic description of ‘third generation’ synthetic cannabinoids.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the future use and purpose of Temporary Class Drug Orders (TCDOs).

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the future use and purpose of Temporary Class Drug Orders (TCDOs).

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the future use and purpose of Temporary Class Drug Orders (TCDOs).

Letter from Advisory Council on the Misuse of Drugs (ACMD) to ministers, providing advice on independent prescribing of controlled drugs by paramedics.

Letter from Advisory Council on the Misuse of Drugs (ACMD) to ministers, providing advice on independent prescribing of controlled drugs by paramedics.